Skip to main content
SP5007,785.76-0.17%DOW53,732.41-0.20%NASDAQ26,729.16-0.28%BTC$62,945.00-0.85%ETH$1,880.32-0.35%GOLD$4,432.00+0.26%OIL$82.40+1.42%
Smart Investors Daily
Sign InSign Up Free
RE

NASDAQ · REVBW

Revelation Biosciences, Inc.

Healthcare · Biotechnology

$0.01

Down-$0.00 (-4.08%)

Updated Aug 17, 2026, 1:05 AM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
55.69K
P/E ratio
-0.28
Dividend yield
0.00%
52-week range
$0.01 – $0.04
Volume
1K
Avg. volume
53.08K

Price performance

REVBW price history

1M range · 9 trading sessions · Daily adjusted prices

REVBW closed at $0.01 after 9 trading sessions, down 5.00% for the selected period.

Last close
$0.01
Period change
-5.00%
Period low
$0.01
Period high
$0.01
Daily close
View OHLC price history
REVBW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 14, 2026$0.0095$0.0095$0.0095$0.00951K
Aug 12, 2026$0.0098$0.0098$0.0098$0.00982K
Aug 11, 2026$0.0065$0.0095$0.0065$0.00951.9K
Jul 30, 2026$0.0098$0.0098$0.0098$0.0098100
Jul 29, 2026$0.0065$0.0091$0.0065$0.0095.2K
Jul 24, 2026$0.01$0.01$0.01$0.01141
Jul 23, 2026$0.0099$0.0099$0.0099$0.0099100
Jul 21, 2026$0.007$0.0094$0.0064$0.009132.94K
Jul 20, 2026$0.01$0.01$0.01$0.011.61K

Latest REVBW news

The latest Smart Investors Daily articles mentioning REVBW.

Stock researchCompany · Overview

REVBW research

Overview

Company profile and research snapshot.

Company profile

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · Jul 26, 2022

Revelation Biosciences Inc. Announces Pricing of $5 Million Public Offering

SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment of disease, today announced the pricing of a public offering of 8,333,334 shares of its common stock, together with warrants to purchase up to 8,333,334 shares of its common stock at an offering price to the public of $0.60 per share and associated warrant. The warrants will have an exercise price of $0.60 per share, are exercisable upon issuance, and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about July 28, 2022, subject to the satisfaction of customary closing conditions.

GlobeNewswire Inc. · Jul 22, 2022

Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

SAN DIEGO, July 22, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today announced topline data for its Phase 1b CLEAR clinical study to evaluate the effect of intranasal REVTx-99b on nasal challenge allergen in participants with allergic rhinitis to rye grass pollen.

GlobeNewswire Inc. · Jan 24, 2022

Revelation Biosciences Raises $7.76 Million in Equity Financing

SAN DIEGO, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today that it has entered into a definitive agreement with a leading healthcare-focused institutional investor, pursuant to which the Company agreed to sell 1,293,126 shares of Common Stock (“Shares”) at a gross purchase price of $3.00 per Share. Additionally, Revelation has agreed to issue to the investor unregistered warrants to purchase up to 2,586,667 shares (the “Common Warrants”), as well as unregistered pre-funded warrants to purchase up to 1,239,541 shares (the “Pre-Funded Warrants” and together with the Common Warrants, the “Warrants”) in a concurrent private placement. The Common Warrants have an exercise price of $3.29 per share, will become exercisable in six months after their date of issuance and will expire five and a half years from their date of issuance. The Pre-Funded Warrants have been funded to the amount of $3.00 with $0.0001 payable on exercise.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By